Snapshot

The Priority Review pathway has been developed by the  Pharmaceuticals and Medical Devices Agency of Japan.

This pathway facilitates activities during development.

It is an abridged review (a reliance pathway).

When relevant, the agency relies on prior decisions from EU-EMA Europe Japan

Target time assessment is 9 months.